Barclays
PRLD icon

Barclays’s Prelude Therapeutics PRLD Stock Holding History

Barclays’s Portfolio PRLD Stock Details PRLD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$77.4K Buy
14,529
+5,929
+69% +$25.8K ﹤0.01% 4160
2026
Q1 		$29.4K Sell
8,600
-2
-0% -$5 ﹤0.01% 4488
2025
Q4 		$24.9K Sell
8,602
-110
-1% -$186 ﹤0.01% 4845
2025
Q3 		$12.5K Buy
8,712
+110
+1% +$110 ﹤0.01% 5002
2025
Q2 		$6.96K Sell
8,602
-14,543
-63% -$12.6K ﹤0.01% 4942
2025
Q1 		$17.8K Sell
23,145
-6,628
-22% -$6.18K ﹤0.01% 4801
2024
Q4 		$38K Buy
29,773
+2,608
+10% +$3.46K ﹤0.01% 4815
2024
Q3 		$56.2K Buy
27,165
+12,564
+86% +$58.2K ﹤0.01% 4719
2024
Q2 		$55.6K Sell
14,601
-5,786
-28% -$23.5K ﹤0.01% 4166
2024
Q1 		$96.6K Sell
20,387
-10,139
-33% -$39.4K ﹤0.01% 4448
2023
Q4 		$130K Buy
30,526
+17,210
+129% +$52.4K ﹤0.01% 4563
2023
Q3 		$41.1K Buy
13,316
+7,264
+120% +$27.3K ﹤0.01% 3949
2023
Q2 		$27.2K Sell
6,052
-4,270
-41% -$25.5K ﹤0.01% 4069
2023
Q1 		$58.8K Sell
10,322
-80,502
-89% -$491K ﹤0.01% 4392
2022
Q4 		$549K Buy
90,824
+85,656
+1,657% +$549K ﹤0.01% 3254
2022
Q3 		$34K Buy
5,168
+1,108
+27% +$7.47K ﹤0.01% 3898
2022
Q2 		$21K Sell
4,060
-1,817
-31% -$9.25K ﹤0.01% 4381
2022
Q1 		$40K Buy
+5,877
New +$53.8K ﹤0.01% 4202

Other funds holding PRLD

O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $767M AUM 119.71% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return

Barclays's PRLD Position: Q2 2026 in Review

Barclays increased its Prelude Therapeutics (PRLD) stake by 69% in Q2 2026, buying an estimated $25.8K and bringing the position to 14,529 shares worth $77.4K. The position accounts for ﹤0.01% of the portfolio, ranked #4160.

Barclays first reported a position in PRLD in Q1 2022 and has held it in 18 quarters since. The position peaked at $549K in Q4 2022. 75 funds tracked by Wall St. Rank hold PRLD as of Q2 2026.

  • Barclays held 14,529 shares of Prelude Therapeutics worth $77.4K as of Q2 2026.
  • Barclays bought 5,929 Prelude Therapeutics shares in Q2 2026, an estimated $25.8K.
  • Prelude Therapeutics made up ﹤0.01% of Barclays's portfolio in Q2 2026, its #4160 holding.
  • Barclays first reported a position in Prelude Therapeutics in Q1 2022 and has held it in 18 quarters since.
  • Barclays's Prelude Therapeutics position peaked at $549K in Q4 2022.
  • 75 funds tracked by Wall St. Rank held Prelude Therapeutics as of Q2 2026.

Based on Barclays's 13F filing for Q2 2026, filed 14 Aug 2026.